Harel details 6.3% Teva (NYSE: TEVA) ownership in Schedule 13G/A

Rhea-AI Filing Summary

Harel Insurance Investments & Financial Services Ltd filed an amended Schedule 13G reporting beneficial ownership of 72,325,555 Teva Pharmaceutical Industries Ltd ordinary shares, representing 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025.

Harel explains that 70,039,163 shares are held for public investors through various funds and insurance products managed by its subsidiaries, 1,090,246 shares are held in third-party client accounts, and 1,196,146 shares are held for its own account. Harel disclaims beneficial ownership of more than the 1,196,146 shares held for its own account.

The filing shows Harel has no sole voting or dispositive power, with shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares. Harel certifies the holdings are not for the purpose of changing or influencing control of Teva.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Teva Pharmaceutical Industries Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 0.10 per share

(Title of Class of Securities)

M8769Q102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M8769Q102

1

Names of Reporting Persons

Harel Insurance Investments & Financial Services Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 71,235,309.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 72,325,555.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

72,325,555.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: * With regard to the date of event that requires filing, see the explanatory note in Item 4. With regard to Rows (6), (8) and (9), please see Item 4. Row (11) is based on 1,149,812,898 Ordinary Shares issued and outstanding as of December 31, 2025 (as reported by the Issuer in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 3, 2026).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Teva Pharmaceutical Industries Ltd
(b)	Address of issuer's principal executive offices: 124 Dvora Hanevi'a Street, Tel Aviv, Israel, 6944020
Item 2.
(a)	Name of person filing: Harel Insurance Investments & Financial Services Ltd.
(b)	Address or principal business office or, if none, residence: 3 Aba Hillel Street, Ramat Gan 52118, Israel
(c)	Citizenship: Israel
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.10 per share
(e)	CUSIP No.: M8769Q102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Of the 72,325,555 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person, (i) 70,039,163 Ordinary Shares are held for members of the public through, among others, provident funds and/or mutual funds and/or pension funds and/or insurance policies and/or exchange traded funds, which are managed by subsidiaries of the Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, (ii) 1,090,246 Ordinary Shares are held by third-party client accounts managed by a subsidiary of the Reporting Person as portfolio managers, which subsidiary operates under independent management and makes independent investment decisions and has no voting power in the securities held in such client accounts, and (iii) 1,196,146 Ordinary Shares are beneficially held for its own account. Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of more than 1,196,146 Ordinary Shares covered by this Statement.
(b)	Percent of class: See Row (11) of the cover page of the Reporting Person above.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See Row (6) of the cover page of the Reporting Person above and note in Item 4 above.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See Row (8) of the cover page of the Reporting Person above and note in Item 4 above.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Harel Insurance Investments & Financial Services Ltd

Signature:	/s/ Alon Kaufman
Name/Title:	Alon Kaufman/Vice President
Date:	02/09/2026

FAQ

What stake in Teva Pharmaceutical (TEVA) does Harel report in this Schedule 13G/A?

Harel reports beneficial ownership of 72,325,555 Teva ordinary shares, equal to 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025. This reflects aggregated holdings across funds, client accounts, and Harel’s own account.

How many Teva (TEVA) shares does Harel hold for its own account?

Harel states it beneficially holds 1,196,146 Teva ordinary shares for its own account. The rest of the reported 72,325,555 shares are held for public investors and third-party clients through subsidiaries, which Harel says operate with independent management.

How are Harel’s Teva (TEVA) holdings allocated across clients and funds?

Of the 72,325,555 Teva shares, Harel reports 70,039,163 shares held for public investors via provident, mutual, pension, insurance, and ETF products, 1,090,246 shares in third-party client accounts, and 1,196,146 shares for its own account, all aggregated for reporting.

What voting and dispositive power does Harel report over Teva (TEVA) shares?

Harel reports no sole voting or dispositive power, but shared voting power over 71,235,309 Teva shares and shared dispositive power over 72,325,555 shares. Subsidiaries managing many of these holdings are described as operating under independent management.

Does Harel claim beneficial ownership of all Teva (TEVA) shares reported?

Harel expressly states the filing should not be read as an admission that it is the beneficial owner of more than 1,196,146 Teva shares, which are held for its own account. The remaining shares are held for public investors and third-party clients through its subsidiaries.

Is Harel seeking to influence control of Teva Pharmaceutical (TEVA)?

Harel certifies the Teva securities were not acquired and are not held for the purpose of changing or influencing control of Teva. It also states the holdings are not part of any control-related transaction, other than activities related to certain nomination rules cited.